Baxter to buy Gambro for $2.8 billion to boost dialysis

, Bloomberg


Baxter International, the U.S. maker of blood products and intravenous drugs, agreed to buy Swedish kidney-dialysis competitor Gambro AB for $2.8 billion to expand its dialysis-equipment business.

This premium content is reserved for Daily Business Review subscribers.

Continue reading by getting started with a subscription.

Already a subscriber? Log in now

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article #1202580210203

Thank you!

This article's comments will be reviewed.